Back to Browse Journals » Nutrition and Dietary Supplements » Volume 1

Clinical evidence supporting the use of an activated clinoptilolite suspension as an agent to increase urinary excretion of toxic heavy metals

Authors James L Flowers, Stewart A Lonky, Erik J Deitsch

Published 4 November 2009 Volume 2009:1 Pages 11—18

DOI https://dx.doi.org/10.2147/NDS.S8043

Review by Single-blind

Peer reviewer comments 4

James L Flowers1, Stewart A Lonky2, Erik J Deitsch3

1Eno Research and Development, Inc., Hillsborough, NC, USA; 2University of California at Los Angeles, Los Angeles, CA, USA; 3Wellness Industries, LLC, Parkland, FL USA

Abstract: Effective treatment of chronic illness resulting from the long-term buildup of heavy metals in the body, such as chelation therapy, presents numerous clinical challenges, including undesirable side effects and unpredictable efficacy. Use of a naturally occurring zeolite, clinoptilolite, to remove these toxic substances may offer an efficacious and safe alternative to the traditional approaches. This study was designed to evaluate the ability of activated clinoptilolite suspended in water (ACS) to remove heavy metals from the body through urinary excretion without the undesirable removal of physiologically important electrolytes. The protocol utilized two treatment groups, each consisting of eleven healthy men aged 36 to 70 years. Volunteers were given a commercially available version of the study substance for seven days (Group 1) and 30 days (Group 2) and urine samples were collected at specified time points in the study. Changes in urinary concentration of the heavy metals were measured by inductively coupled plasma mass spectrometry and compared to the baseline. Also, serum samples were obtained from five individuals in each group and serum electrolytes were measured prior to and after taking the product. Participants in both groups had increased concentrations of heavy metals in the urine with the peak excretion at around day 4. No clinically significant alterations in serum electrolyte levels were seen at either seven or 30 days on ACS. In conclusion, this study demonstrates that the daily use of an activated clinoptilolite suspension represents a potentially safe and effective way to remove toxic heavy metals from the body through increased urinary excretion without removing clinically detrimental amounts of vital electrolytes.

Keywords: zeolite, clinoptilolite, heavy metals, toxins, atomic absorption spectroscopy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Survey of Japanese ophthalmic surgeons regarding perioperative disinfection and antibiotic prophylaxis in cataract surgery

Matsuura K, Mori T, Miyamoto T, Suto C, Saeki Y, Tanaka S, Kawamura H, Ohkubo S, Tanito M, Inoue Y

Clinical Ophthalmology 2014, 8:2013-2018

Published Date: 29 September 2014

Contraceptive implants: current perspectives

Rowlands S, Searle S

Open Access Journal of Contraception 2014, 5:73-84

Published Date: 23 September 2014

Non-adherence to topical treatments for actinic keratosis

Shergill B, Zokaie S, Carr AJ

Patient Preference and Adherence 2014, 8:35-41

Published Date: 17 December 2013

Topical azithromycin or ofloxacin for endophthalmitis

Stewart MW, Stewart ML

Clinical Ophthalmology 2013, 7:35-38

Published Date: 31 December 2012

Erratum

Schuelert N, Russell FA, McDougall JJ

Orthopedic Research and Reviews 2011, 3:9-10

Published Date: 1 March 2011

Characterizing the thermal environment of small mammals: what should we be measuring, and how?

Joy C Coleman, Colleen T Downs

Open Access Animal Physiology 2010, 2:47-59

Published Date: 10 September 2010

Topical administration of adrenergic receptor pharmaceutics and nerve growth factor

Jena J Steinle

Clinical Ophthalmology 2010, 4:605-610

Published Date: 29 June 2010